Tradipitant to be evaluated for reducing GLP-1R agonist-induced nausea and vomiting in overweight adults

Nausea and vomiting are common and often dose-limiting side effects associated with GLP-1 receptor agonist (GLP-1R) therapies, which are widely used for type 2 diabetes and obesity management. These gastrointestinal adverse events can significantly impact patient adherence and quality of life, leading many to discontinue treatment or avoid dose escalation. Current management strategies are often symptomatic and non-specific, highlighting a critical unmet need for targeted interventions that can improve tolerability and enable patients to achieve optimal therapeutic benefits from GLP-1R agonists. Tradipitant, an NK-1 receptor antagonist, offers a potential mechanism to address these symptoms.

The Thetis Study is a Phase 3, randomized, double-blind, placebo-controlled clinical trial designed to evaluate Tradipitant's efficacy. Healthy overweight, class I, or class II obese volunteers will be enrolled. Participants will receive a GLP-1R agonist, followed by either Tradipitant or a placebo. The study features two distinct treatment arms, though specific dosing regimens for Tradipitant or the GLP-1R agonist, route of administration, frequency, or duration are not detailed in the abstract. The primary endpoint will focus on measuring the effects on nausea and vomiting.

As this is an active, recruiting Phase 3 clinical trial (NCT07446439), no efficacy or safety results are currently available. The study's primary objective is to quantify the effect of Tradipitant on the incidence and severity of nausea and vomiting following GLP-1R agonist administration. This rigorous, placebo-controlled design aims to provide definitive data on whether Tradipitant can offer a significant clinical benefit in managing these common adverse effects. Secondary objectives will likely include assessments of tolerability, quality of life metrics, and potentially pharmacokinetic interactions, though these specific details are not provided in the abstract. The trial is designed to establish a clear profile for Tradipitant's utility in this context.

The study aims to determine if Tradipitant can significantly reduce GLP-1R agonist-induced nausea and vomiting in healthy overweight or obese individuals.